Lisa Tietze

Lisa Tietze

Auto-generated profile, based on publicly available information

Lisa Tietze

Department of Immunology, Oslo University Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
TTTrung The Tran
Trung The Tran
EVEline Benno Vaage
Eline Benno Vaage
AMAdi Mehta
Adi Mehta
ACAdity Chopra
Adity Chopra
LTLisa Tietze
Lisa Tietze
FLFridtjof Lund-Johansen
Fridtjof Lund-Johansen
Diagnostic assays currently used to monitor the efficacy of COVID-19 vaccines measure levels of antibodies to the receptor-binding domain of ancestral SARS-CoV-2 (RBDwt). However, the predictive value for protection against new variants of concern (VOCs) has not been firmly established. Here, we used bead-based arrays and flow cytometry to measure binding of antibodies to spike proteins and receptor-binding domains (RBDs) from VOCs in 12,000 serum samples. Effects of sera on RBD-ACE2 interactions were measured as a proxy for neutralizing antibodies. The samples were obtained from healthy individuals or patients on immunosuppressive therapy who had received two to four doses of COVID-19 vaccines and from COVID-19 convalescents. The results show that anti-RBDwt titers correlate with the levels of binding- and neutralizing antibodies against the Alpha, Beta, Gamma, Delta, Epsilon and Omicron variants. The benefit of multiplexed analysis lies in the ability to measure a wide range of anti-RBD titers using a single dilution of serum for each assay. The reactivity patterns also yield an internal reference for neutralizing activity and binding antibody units per milliliter (BAU/ml). Results obtained with sera from vaccinated healthy individuals and patients confirmed and extended results from previous studies on time-dependent waning of antibody levels and effects of immunosuppressive agents. We conclude that anti-RBDwt titers correlate with levels of neutralizing antibodies against VOCs and propose that our method may be implemented to enhance the precision and throughput of immunomonitoring.

1 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AAAina Karen Anthi
Aina Karen Anthi
AKAnette Kolderup
Anette Kolderup
EVEline Benno Vaage
Eline Benno Vaage
MBMalin Bern
Malin Bern
SBSopisa Benjakul
Sopisa Benjakul
JAJan Terje Andersen
Jan Terje Andersen
Although vaccines are usually given intramuscularly, the intranasal delivery route may lead to better mucosal protection and limit the spread of respiratory virus while easing administration and improving vaccine acceptance. The challenge, however, is to achieve delivery across the selective epithelial cell barrier. Here we report on a subunit vaccine platform, in which the antigen is genetically fused to albumin to facilitate FcRn-mediated transport across the mucosal barrier in the presence of adjuvant. Intranasal delivery in conventional and transgenic mouse models induces both systemic and mucosal antigen-specific antibody responses that protect against challenge with SARS-CoV-2 or influenza A. When benchmarked against an intramuscularly administered mRNA vaccine or an intranasally administered antigen fused to an alternative carrier of similar size, only the albumin-based intranasal vaccine yields robust mucosal IgA antibody responses. Our results thus suggest that this needle-free, albumin-based vaccine platform may be suited for vaccination against respiratory pathogens.

25 January 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
TTTrung The Tran
Trung The Tran
EVEline Benno Vaage
Eline Benno Vaage
AMAdi Mehta
Adi Mehta
ACAdity Chopra
Adity Chopra
LTLisa Tietze
Lisa Tietze
FLFridtjof Lund-Johansen
Fridtjof Lund-Johansen